Role of cytoreductive surgery in recurrent ovarian cancer

Therapy

Volumn 7, Issue 1, 2010, Pages 87-95

  Fagotti, Anna ^a   Gallotta, Valerio ^a   Romano, Federico ^a   Fanfani, Francesco ^a   Rossitto, Cristiano ^a   Vizzielli, Giuseppe ^a   Costantini, Barbara ^a   Scambia, Giovanni ^a  

^a NONE

Author keywords

Gynecologic oncology; HIPEC; Hyperthermic intraoperative peritoneal chemotherapy; Recurrent ovarian cancer; Secondary cytoreduction

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN;

ANTINEOPLASTIC ACTIVITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLON RESECTION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CYTOREDUCTIVE SURGERY; CYTOTOXICITY; DIAGNOSTIC ACCURACY; DRUG TARGETING; HUMAN; HYPERTHERMIC THERAPY; INTRAOPERATIVE PERIOD; LAPAROSCOPIC SURGERY; LIVER METASTASIS; LIVER RESECTION; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PERITONEUM METASTASIS; POSITRON EMISSION TOMOGRAPHY; PREDICTION; RECURRENT CANCER; REVIEW; SPLEEN CANCER; SPLENECTOMY; SYSTEMIC THERAPY; TREATMENT OUTCOME;

EID: 75449114678     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/thy.09.90     Document Type: Review

References (84)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J. Clin. 59(4), 225-249 (2009).
2. Munkarah AR, Coleman RL: Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecol. Oncol. 95(2), 273-280 (2004).
3. Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M: The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am. J. Obstet. Gyneol. 70, 974-980 (1994).
4. Bristow RE, Tomacruz RS, Armstrong DK, Timble EL, Montz FJ: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 20, 1248-1259 (2002). ■ Underscores with meta-analyses the importance of surgical effort and residual tumor in gynecologic oncology.
5. Boente MP, Chi DS, Hoskins WJ: The role of surgery in the management of ovarian cancer: primary and interval cytoreductive surgery. Semin. Oncol. 25, 326-334 (1998).
6. Markman M: "Recurrence within 6 months of platinum therapy": an adequate definition of "platinum-refractory" ovarian cancer? Gynecol. Oncol. 69(2), 91-92 (1998).
7. Bristow RE, Puri I, Chi DS: Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol. Oncol. 112(1), 265-274 (2009). ■■ Underscores with meta-analyses the importance of surgical effort and its correlation with the prognosis of patients with relapsed ovarian cancer.
8. Harries M, Gore M: Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. Lancet Oncol. 3(9), 537-545 (2002).
9. Cannistra SA. Is there a "best" choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer? J. Clin. Oncol. 20(5), 1158-1160 (2002).
10. Cannistra SA, Bast RC Jr, Berek JS et al.: Progress in the management of gynecologic cancer: consensus summary statement. J. Clin. Oncol. 21(10 Suppl.), S129-S132 (2003).
11. Dizon DS, Dupont J, Anderson S et al.: Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience. Gynecol. Oncol. 91(3), 584-590 (2003).
12. Berek JS, Hacker NF, Lagasse LD, Nieberg RK, Elashoff RM: Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet. Gynecol. 61(2), 189-193 (1983).
13. Morris M, Gershenson DM, Wharton JT, Copeland LJ, Edwards CL, Stringer CA: Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol. Oncol. 34(3), 334-338 (1989).
14. Jänicke F, Hölscher M, Kuhn W et al.: Radical surgical procedure improves survival time in patients with recurrent ovarian Cancer Cancer 70(8), 2129-2136 (1992).
15. Segna RA, Dottino PR, Mandeli JP, Konsker K, Cohen CJ: Secondary cytoreduction for ovarian cancer following cisplatin therapy. J. Clin. Oncol. 11(3), 434-439 (1993).
16. Eisenkop SM, Friedman RL, Wang HJ: Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study. Cancer 76(9), 1606-1614 (1995).
17. Vaccarello L, Rubin SC, Vlamis V et al.: Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response. Gynecol. Oncol. 57(1), 61-65 (1995).
18. Gadducci A, Iacconi P, Cosio S, Fanucchi A, Cristofani R, Riccardo Genazzani A: Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gynecol. Oncol. 79(3), 344-349 (2000).
19. Zang RY, Zhang ZY, Li ZT et al.: Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer. J. Surg. Oncol. 75(1), 24-30 (2000).
20. Munkarah A, Levenback C, Wolf JK et al.: Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer. Gynecol. Oncol. 81(2), 237-241 (2001).
21. Tay EH, Grant PT, Gebski V, Hacker NF: Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet. Gynecol. 99(6), 1008-1013 (2002).
22. Gronlund B, Lundvall L, Christensen IJ, Knudsen JB, Høgdall C: Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum. Eur. J. Surg. Oncol. 31(1), 67-73 (2005).
23. Güngör M, Ortaç F, Arvas M, Kösebay D, Sönmezer M, Köse K: The role of secondary cytoreductive surgery for recurrent ovarian cancer. Gynecol. Oncol. 97(1), 74-79 (2005).
24. Ayhan A, Gultekin M, Taskiran C et al.: The role of secondary cytoreduction in the treatment of ovarian cancer: Hacettepe University experience. Am. J. Obstet. Gynecol. 194(1), 49-56 (2006).
25. Chi DS, McCaughty K, Diaz JP et al.: Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 106(9), 1933-1939 (2006). ■ Focuses attention on selection criteria for secondary cytoreduction.
26. Onda T, Yoshikawa H, Yasugi T, Yamada M, Matsumoto K, Taketani Y: Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection. Br. J. Cancer 92(6), 1026-1032 (2005).
27. Eisenkop SM, Friedman RL, Spirtos NM: The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 88(1), 144-153 (2000).
28. Ferrandina G, Legge F, Salutari V, Paglia A, Testa A, Scambia G: Impact of pattern of recurrence on clinical outcome of ovarian cancer patients: clinical considerations. Eur. J. Cancer 42(14), 2296-2302 (2006).
29. Harter P, du Bois A: The role of surgery in ovarian cancer with special emphasis on cytoreductive surgery for recurrence. Curr. Opin. Oncol. 17(5), 505-514 (2005).
30. Harter P, du Bois A, Hahmann M et al.; Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Committee, AGO Ovarian Cancer Study Group: Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann. Surg. Oncol. 13(12), 1702-1710 (2006). ■ Large, multicenter retrospective review that led to the design of an algorithm that suggests that patients with a good performance status and a disease-free interval greater than 6 months should undergo secondary cytoreduction.
31. Bristow RE, Duska LR, Lambrou NC et al.: A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer 89(7), 1532-1540 (2000). ■ Proposed the first objective radiological model to predict surgical outcome in ovarian cancer patients.
32. Dowdy SC, Mullany SA, Brandt KR, Huppert BJ, Cliby WA: The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma. Cancer 101(2), 346-352 (2004).
33. Funt SA, Hricak H, Abu-Rustum N, Mazumdar M, Felderman H, Chi DS: Role of CT in the management of recurrent ovarian cancer. AJR Am. J. Roentgenol. 182, 393-398 (2004).
34. Bristow RE, del Carmen MG, Pannu HK et al.: Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol. Oncol. 90(3), 519-528 (2003). ■ Proposed the use of positron emission tomography/computed tomography (PET/CT) in recurrent ovarian cancer.
35. Simcock B, Neesham D, Quinn M, Drummond E, Milner A, Hicks RJ: The impact of PET/CT in the management of recurrent ovarian cancer. Gynecol. Oncol. 103, 271-276 (2006).
36. Takekuma M, Maeda M, Ozawa T, Yasumi K, Torizuka T: Positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer. Int. J. Clin. Oncol. 10(3), 177-181 (2005).
37. Thrall MM, DeLoia JA, Gallion H, Avril N: Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Gynecol. Oncol. 105, 17-22 (2007).
38. Fulham MJ, Carter J, Baldey A, Hicks RJ, Ramshaw JE, Gibson M: The impact of PET-CT in suspected recurrent ovarian cancer: A prospective multi-centre study as part of the Australian PET Data Collection Project. Gynecol. Oncol. 112(3), 462-468 (2009). ■■ Proposed the use of PET/CT in recurrent ovarian cancer in a prospective multicenter study.
39. Fagotti A, Ferrandina G, Fanfani F et al.: A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann. Surg. Oncol. 13(8), 1156-1161 (2006). ■■ First proposed an objective laparoscopic model to predict optimal cytoreduction in ovarian cancer.
40. Fagotti A, Fanfani F, Rossitto C et al.: A treatment selection protocol for recurrent ovarian cancer patients: the role of FDG-PET/CT and staging laparoscopy. Oncology 75(3-4), 152-158 (2008). ■■ Suggests that the combination of fluorodeoxyglucose-PET and laparoscopy has a significant effect on the multimodal approach to the population of patients with recurrent ovarian cancer.
41. Merideth MA, Cliby WA, Keeney GL, Lesnick TG, Nagorney DM, Podratz KC: Hepatic resection for metachronous metastases from ovarian carcinoma. Gynecol. Oncol. 89(1), 16-21 (2003).
42. Yoon SS, Jarnagin WR, Fong Y et al.: Resection of recurrent ovarian or fallopian tube carcinoma involving the liver. Gynecol. Oncol. 91(2), 383-388 (2003).
43. Magtibay PM, Adams PB, Silverman MB, Cha SS, Podratz KC: Splenectomy as part of cytoreductive surgery in ovarian cancer. Gynecol. Oncol. 102(2), 369-374 (2006).
44. Bristow RE, Peiretti M, Gerardi M et al.: Secondary cytoreductive surgery including rectosigmoid colectomy for recurrent ovarian cancer: operative technique and clinical outcome. Gynecol. Oncol. 114(2), 173-177 (2009).
45. Tamussino KF, Lim PC, Webb MJ, Lee RA, Lesnick TG: Gastrointestinal surgery in patients with ovarian cancer. Gynecol. Oncol. 80(1), 79-84 (2001).
46. Salani R, Santillan A, Zahurak ML et al.: Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer 109(4), 685-691 (2007).
47. Blanchard P, Plantade A, Pagès C et al.: Isolated lymph node relapse of epithelial ovarian carcinoma: outcomes and prognostic factors. Gynecol. Oncol. 104(1), 41-45 (2007).
48. Legge F, Petrillo M, Adamo V, Pisconti S, Scambia G, Ferrandina G: Epithelial ovarian cancer relapsing as isolated lymph node disease: natural history and clinical outcome. BMC Cancer 8, 367 (2008). ■■ Suggests that ovarian lymph node relapses have a history quite different from intraperitoneal recurrent disease.
49. Chi DS, Eisenhauer EL, Zivanovic O et al.: Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol. Oncol. 114(1), 26-31 (2009). ■■ Retrospectively underscores the importance of radical debulking in ovarian cancer.
50. Bijelic L, Jonson A, Sugarbaker PH: Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer. Ann. Oncol. 18, 1943-1950 (2007). ■■ Interesting review in which the morbidity, mortality and survival benefit of cytoreductive surgery combined with heated intraoperative intraperitoneal chemotherapy or early postoperative intraperitoneal chemotherapy was analyzed.
51. Rufian S, Munoz-Casares FC, Briceno J et al.: Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. J. Surg. Oncol. 94, 316-324 (2006).
52. Reichman TW, Cracchiolo B, Sama J et al.: Cytoreductive surgery and intraoperative hyperthermic chemoperfusion for advanced ovarian carcinoma. J. Surg. Oncol. 90, 51-58 (2005).
53. Look M, Chang D, Sugarbaker PH: Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int. J. Gynecol. Cancer 14, 35-41 (2004).
54. Piso P, Dahlke MH, Loss M et al.: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer. World J. Surg. Oncol. 2, 21 (2004).
55. van der Vange N, van Goethem AR, Zoetmulder FAN et al.: Extensive cytoreductive surgery combined with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot. Eur. J. Surg. Oncol. 26, 663-668 (2000).
56. Hadi R, Saunders V, Utkina O et al.: Review of patients with peritoneal malignancy treated with peritonectomy and heated intraperitoneal chemotherapy. ANZ J. Surg. 76, 156-161 (2006).
57. Bozzetti F, Yu W, Baratti D, Kusamura S, Deraco M: Locoregional treatment of peritoneal carcinomatosis from gastric cancer. J. Surg. Oncol. 98(4), 273-276 (2008).
58. Yan TD, Links M, Fransi S et al.: Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy - a journey to becoming a Nationally Funded Peritonectomy Center. Ann. Surg. Oncol. 14(8), 2270-2280 (2007).
59. Sugarbaker PH, Chang D: Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann. Surg. Oncol. 6, 727-731 (1999).
60. Smeenk RM, Verwaal VJ, Antonini N, Zoetmulder FA: Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann. Surg. 245(1), 104-109 (2007).
61. Esquivel J: Cytoreductive surgery for peritoneal malignancies - devolpment of standards of care for the community. Surg. Oncol. Clin. N. Am. 16(3), 653-666 (2007).
62. Giovanella BC, Stehlin Jr JS, Morgan AC: Selective lethal effect of supranormal temperatures on human neoplastic cells. Cancer Res. 36(11 Part 1), 3944-3950 (1976).
63. Alberts DS, Markman M, Muggia F et al.: Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer. Gynecol. Oncol. 103(3), 783-792 (2006).
64. Hahn GM: Potential for therapy of drugs and hyperthermia. Cancer Res. 39(6 Part 2), 22648 (1979).
65. Meyn RE, Corry PM, Fletcher SE, Demetriades M: Thermal enhancement of DNA damage in mammalian cells treated with cis-diamminedichloroplatinum(II). Cancer Res. 40(4), 1136-1139 (1980).
66. Alberts DS, Peng YM, Chen HS, Moon TE, Cetas TC, Hoeschele JD: Therapeutic synergism of hyperthermia-cis-platinum in a mouse tumor model. J. Natl Cancer Inst. 65(2), 455-461 (1980).
67. Los G, van Vugt MJ, Pinedo HM: Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. Br. J. Cancer 69(2), 235-241 (1994).
68. Akaboshi M, Tanaka Y, Kawai K, Akuta K, Masunaga S, Ono K: Effect of hyperthermia on the number of platinum atoms binding to DNA of HeLa cells treated with 195mPtradiolabelled cisdiaminedichloroplatinum(II). Int J. Radiat. Biol. 66(2), 215-220 (1994).
69. Herman TS, Teicher BA, Cathcart KN, Kaufmann ME, Lee JB, Lee MH: Effect of hyperthermia on cis-diamminedichloroplatinum( II) (rhodamine 123)2[tetrachloroplatinum(II)] in a human squamous cell carcinoma line and a cis-diamminedichloroplatinum(II)-resistant subline. Cancer Res. 48(18), 5101-5105 (1988).
70. van de Vaart PJ, van der Vange N, Zoetmulder FA et al.: Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur. J. Cancer 34(1), 148-154 (1998).
71. Deraco M, Rossi CR, Pennacchioli E et al.: Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a Phase II clinical study. Tumori 7, 1206 (2001).
72. Panteix G, Beaujard A, Garbit F et al.: Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy. Anticancer Res. 22, 1329-1336 (2002).
73. Helm CW, Martin RS, Metzinger DS, Edwards RP: Secondary surgical cytoreduction and hyperthermic intraperitoneal chemotherapy for recurrent ovarian and endometrial cancer. Int. Gynecol. Cancer Soc. 14(Suppl. 1), 167 (2004).
74. Kober F, Heiss A, Roka R: Diffuse and gross peritoneal carcinomatosis treated intraperitoneal hyperthermic chemoperfusion. In: Peritoneal Carcinomatosis: Principles Of Management. Sugarbaker PH (Ed.). Kluwer Academic Publishers, MA, USA, 211-219 (1996).
75. Jacquet P, Sugarbaker PH: Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J. Exp. Clin. Cancer Res. 15, 46-58 (1996).
76. Yan TD, Brun EA, Cerruto CA et al.: Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann. Surg. Oncol. 14, 41-49 (2007).
77. Sugarbaker PH: Are there surgical options to peritoneal carcinomatosis? Ann. Surg. 242, 748-750 (2005).
78. Nonaka D, Kusamura S, Baratti D et al.: Diffuse malignant mesothelioma of peritoneum: a clinicopathologic study of 35 patients treated locoregionally at a single institution. Cancer 104, 2181-2188 (2005).
79. Verwaal VJ, van Ruth S, de Bree E et al.: Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal origin. J. Clin. Oncol. 21, 3737-3743 (2003).
80. Hunter RW, Alexander ND, Soutter WP: Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis? Am. J. Obstet. Gynecol. 166, 504-511 (1992).
81. Flessner M, Lofthouse J, El Rashed Z: Improving contact area between peritoneum and intraperitoneal therapeutic solutions. J. Am. Soc. Nephrol. 12, 807-813 (2001).
82. Scarabelli C, Gallo A, Carbone A: Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol. Oncol. 83, 504-512 (2001).
83. Fagotti A, Paris I, Grimolizzi F et al.: Secondary cytoreduction plus oxaliplatinbased HIPEC in platinum-sensitive recurrent ovarian cancer patients: a pilot study. Gynecol. Oncol. 113(3), 335-340 (2009). ■■ Demonstrated that preoperative evaluation allowed a complete cytoreduction in 100% of the patients, which is an excellent result when compared with the 50% complete cytoreduction that was demonstrated in a recent meta-analysis on secondary surgery.
84. deBree E, Rosing H, Filis D et al.: Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study. Ann. Surg. Oncol. 15(4), 1183-1192 (2008).